Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFG316 (Tesidolumab) in PNH
NCT02534909Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2015
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of tesidolumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Started Sep 2015; status: completed.
02
Drugs
tesidolumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT02534909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534909.